121 results on '"Pavletic, Steven Z."'
Search Results
2. Chronic graft-versus-host disease is characterized by high levels and distinctive tissue-of-origin patterns of cell-free DNA
3. Characterization of Hepatic Dysfunction in Subjects Diagnosed With Chronic GVHD by NIH Consensus Criteria
4. Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies
5. Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force
6. Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome Pathogenesis
7. Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-Versus-Host Disease Studies
8. Pleuroparenchymal Fibroelastosis in Patients with Chronic Graft-Versus-Host-Disease: A Rare Delayed Complication of Hematopoietic Stem Cell Transplantation
9. Belumosudil for Patients with Chronic Graft-Versus-Host Disease: Combined Analysis of Failure-Free Survival (FFS) in the KD025-208 and Pivotal Rockstar Trials
10. Salivary ZG16B expression loss follows exocrine gland dysfunction related to oral chronic graft-versus-host disease
11. Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease
12. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report
13. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report
14. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report
15. The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports
16. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report
17. Rehabilitation Interventions in the Multidisciplinary Management of Patients With Sclerotic Graft-Versus-Host Disease of the Skin and Fascia
18. Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)
19. Immune Correlates from a Prospective Trial Suggest Leukotriene Signaling and Alternative Macrophage Activation in Clinical Bronchiolitis Obliterans Syndrome
20. Pathogenic Shifts in the Oral Microbiome Are Associated with Onset of Oral Mucosal Chronic Graft-Versus-Host-Disease
21. BAFF, CXCL9 and CCL15 in Different Clinical Chronic Graft Versus Host Disease Phenotypes
22. Evaluation of Congruency between Patient and Clinician Chronic Graft-Versus-Host Disease Severity Assessment
23. Salivary ZG16B Expression Loss Marks Onset of Oral Chronic Graft-Versus-Host Disease and Exocrine Gland Dysfunction
24. Prospective Phase Ii Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bos Pathogenesis
25. Human pSTAT3-Inhibited Itregs Prevent Gvhd, Maintain Anti-Leukemia Immunity, and Increase Their Potency after Metabolic Reprogramming
26. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
27. Accompanying editorial on paper Neutrophil extracellular traps (NETs) contribute to Pathological Changes of ocular graft-vs.-Host Disease (oGVHD) dry eye: Implications for novel Biomarkers and Therapeutic Strategies by Seungwon An et al.
28. Incidence of Epstein-Barr Virus (EBV) Detection in the Blood, Pre-Emptive Therapy, and EBV-Posttransplantation Lymphoproliferative Disorder (EBV-PTLD) after Allogeneic Hematopoietic Cell Transplantation (HCT) across a Broad Range of HCT Approaches and All Graft Sources
29. Chronic Graft-Versus-Host Disease Abrogates Standard Risk Factors for Malignancy Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
30. Salivary Zymogen Granule Protein 16B Drops at Onset of Chronic Graft-Versus-Host Disease: A Possible Salivary Biomarker for Oral Chronic Graft-Versus-Host Disease
31. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy
32. Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution
33. Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis
34. Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease
35. A Large Cohort Comparison of the New 2014 National Institutes of Health Chronic Graft-Versus-Host Disease Staging Criteria with the 2005 Version in Severely Affected Patients
36. Immunogenicity of HPV Quadrivalent Vaccine in Women after Allogeneic HCT is Comparable to Healthy Volunteers
37. Cytomegalovirus (CMV) Infection and Disease Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation (HCT) Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation From a Single Institution
38. Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-Versus-Host Disease
39. A National Multi-Center Randomized Study to Assess the Accuracy, Reliability, and User Satisfaction of the Ebmt Gvhd App in Graft Versus Host Disease Assessment
40. Early Experience with a Radiation- and Serotherapy-Free Reduced Intensity Conditioning Platform for Allogeneic Bone Marrow Transplantation (alloBMT) in Primary Immunodeficiency (PID)
41. Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients
42. Achalasia in a Patient Undergoing Hematologic Stem Cell Transplant After Exposure to Tacrolimus
43. Allogeneic Bone Marrow Transplantation for Primary Immunodeficiencies: Pilot Trial of a Novel, Reduced Intensity Platform
44. Health Economics of Steroid Refractory Chronic Graft-Versus-Host-Disease Treatments: Cost-Utility Based Meta-Analysis
45. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
46. Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation
47. Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease
48. Erratum to “Salivary Gland Involvement in Chronic Graft-versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation” [Biol Blood Marrow Transplant 16:1362-1369]
49. Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation
50. The ‘EBMT GVHD App' Improves the Accuracy of Graft-Versus-Host-Disease Assessment According to NIH Criteria Compared to Standard Practice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.